Saturday 17 October 2026 Export LMAT’s income statement to Excel — free account

LeMaitre Vascular, Inc.

LMAT Healthcare Medical Instruments & Supplies

LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024. In the quarter to June 2026, revenue grew 9.57%, EPS grew 23.0%, free cash flow fell 28.0% and total debt was flat, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

80.82 2.34 −2.81%

Follow LMAT

Alert me

Market cap: $1.9B
P/E: 27.9×
Fwd P/E: 31.5×
Dividend yield: 1.18%
F-score: 6/9
Altman Z: 6.99
Beneish M: −2.61
Dividend safety: 93/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 30.04

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	3	2	—	4	—	—	—	—	—

Insider Ownership 6.86%

Capital & Financial Ratios $m

Market Cap 1,900.00

Revenue 262.43

Net Income 65.67

Free Cash Flow 73.83

Net Debt (207.15)

Current Ratio 16.31

Debt/Equity 0.40

P/E ratio 27.87

Fwd P/E 31.50

P/S ratio 7.04

P/B ratio 4.40

Past 5Y EPS Growth 19.36%

This Y EPS Growth 13.99%

Next Y EPS Growth 10.66%

Next Y revenue growth 10.78%

Next 5Y EPS Growth 11.16%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 9.25%

10-year low 10-year high

P/S against its own 10 years 61.44%

10-year low 10-year high

P/B against its own 10 years 36.75%

10-year low 10-year high

EV/Sales against its own 10 years 51.42%

10-year low 10-year high

EV/FCF against its own 10 years 2.29%

10-year low 10-year high

Dividends

Payout Ratio 0.33

Annual Dividend Rate 0.95

Annual Dividend Yield 1.18%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	1.00	0.25 0.25 0.25
2025	0.80	0.20 0.20 0.20 0.20
2024	0.64	0.16 0.16 0.16 0.16
2023	0.56	0.14 0.14 0.14 0.14
2022	0.50	0.13 0.13 0.13 0.13
2021	0.44	0.11 0.11 0.11 0.11
2020	0.38	0.10 0.10 0.10 0.10
2019	0.34	0.09 0.09 0.09 0.09
2018	0.28	0.07 0.07 0.07 0.07
2017	0.22	0.06 0.06 0.06 0.06
2016	0.18	0.05 0.05 0.05 0.05

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	105	300	359	376
Receivables	25	30	34	36
Inventory	58	65	70	71
Other	—	—	—	—
	195	402	468	488

	2023	2024	2025	Q'26
Payables	4	2	4	3
ST’ Debt	—	—	—	—
Other	0	1	0	0
	30	31	36	30

Compound Annual Growth %

	10y	5y	3y
Sales	12.28%	14.05%	15.58%
Cash Flow	21.66%	18.48%	47.39%
Earnings	22.23%	22.16%	40.91%
Book Value	17.58%	17.92%	13.63%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	67	70	—	—	—
’25	60	64	61	64	250
’24	53	56	55	56	220
’23	47	50	47	49	193
’22	40	42	39	41	162
’21	36	41	38	40	154
’20	31	25	36	38	129

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	15	16	—	—	—
’25	9	20	29	23	81
’24	5	10	14	15	44
’23	2	12	12	11	37
’22	5	9	7	4	25
’21	6	10	14	5	35
’20	1	5	14	14	35

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	12	14	—	—	—
’25	8	19	26	21	74
’24	4	8	13	13	37
’23	0	9	11	9	29
’22	4	8	7	4	23
’21	5	8	12	4	30
’20	0	5	16	13	34

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.68	0.74	—	—	—
’25	0.48	0.60	0.75	0.68	2.52
’24	0.44	0.52	0.49	0.49	1.93
’23	0.27	0.36	0.33	0.38	1.34
’22	0.27	0.16	0.25	0.25	0.93
’21	0.28	0.40	0.30	0.28	1.25
’20	0.16	0.17	0.37	0.34	1.04

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	12.03	19.82	21.79	22.23	18.76	39.38	38.32	44.02	52.88	71.42	Analyst estimates 2026–2028 Powerpack
	High	25.87	39.88	41.28	37.35	41.86	64.50	56.38	68.67	109.58	105.55
People
People	Employees	397	423	483	479	403	488	617	630	664	655
	Revenue/emp, $m	0.22	0.24	0.22	0.24	0.32	0.32	0.26	0.31	0.33	0.38
Income, $m
Income, $m	Revenue	89	101	106	117	129	154	162	193	220	250
	Gross margin, %	70.59	70.09	70.04	68.12	65.41	65.65	64.89	65.66	68.63	71.53
	EBT	16	21	28	22	27	34	27	39	57	75
	EBT margin, %	18.22	20.92	26.94	18.49	21.15	22.20	17.01	20.40	25.87	30.12
	Net income	11	17	23	18	21	27	21	30	44	58
	Depreciation	4	4	4	5	8	11	9	10	10	11
Per share, $
Per share, $	Revenue	4.82	5.32	5.43	5.92	6.39	7.30	7.36	8.71	9.79	11.03
	Earnings	0.57	0.91	1.18	0.91	1.05	1.27	0.94	1.36	1.96	2.55
	Cash flow	0.91	1.21	1.00	0.72	1.72	1.66	1.15	1.65	1.97	3.59
	Capex	(0.15)	(0.34)	(0.16)	(0.19)	(0.05)	(0.23)	(0.11)	(0.33)	(0.31)	(0.30)
	Free cash flow	0.76	0.87	0.85	0.53	1.67	1.43	1.05	1.33	1.66	3.29
	Book value	4.73	5.79	6.70	7.48	8.52	12.01	12.20	13.41	15.02	17.38
	Shares, m	18	19	19	20	20	21	22	22	22	23
Valuation, ×
Valuation, ×	P/E	44.26	34.58	20.03	39.94	38.57	39.55	47.82	42.01	46.77	31.68
	P/S	5.23	5.85	4.35	6.08	6.34	6.88	6.18	6.51	9.41	7.36
	P/B	5.33	5.38	3.53	4.81	4.75	4.18	3.72	4.23	6.13	4.67
	EV/Sales	4.96	5.44	3.90	5.93	6.42	6.54	5.77	6.06	8.82	6.60
	EV/FCF	31.51	33.39	25.03	66.90	24.57	33.44	40.61	39.78	52.23	22.14
Cash, $m
Cash, $m	Operating cash flow	17	23	20	14	35	35	25	37	44	81
	Capex	(3)	(6)	(3)	(4)	(1)	(5)	(2)	(7)	(7)	(7)
	Free cash flow	14	16	16	10	34	30	23	29	37	74
Balance, $m
Balance, $m	Working capital	49	67	74	71	69	118	136	165	372	432
	Total debt	—	—	—	16	38	14	15	—	168	169
	Net debt	(24)	(42)	(48)	(17)	11	(56)	(68)	(105)	(132)	(190)
	Shareholders’ equity	88	110	130	148	173	254	268	298	337	394
Returns, %
Returns, %	ROA	11.00	15.05	16.42	10.51	9.62	9.86	6.84	9.16	9.80	9.89
	ROIC	16.15	19.36	21.44	10.09	9.80	11.48	8.37	11.90	15.91	20.90
	ROE	12.81	17.41	19.12	12.88	13.23	12.61	7.90	10.64	13.87	15.80

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%	Compare
ATRC AtriCure, Inc.	$2.9B	259×	591×	+12.83% (above 0%: growing)	n/m	−2.79% (below 0%: shrinking)	77.23%	6.29%	Compare
LMAT LeMaitre Vascular, Inc.	$1.9B	27.9×	31.5×	+9.57% (above 0%: growing)	+22.95% (above 0%: growing)	−27.95% (below 0%: shrinking)	72.13%	28.98%
XRAY DENTSPLY SIRONA Inc.	$1.8B	— (loss-making)	27.0×	−4.06% (below 0%: shrinking)	n/m	+252.94% (above 0%: growing)	54.90%	9.13%	Compare
KMTS Kestra Medical Technologies, Ltd.	$1.7B	— (loss-making)	— (loss-making)	+59.88% (above 0%: growing)	n/m	−17.75% (below 0%: shrinking)	56.50%	(121.59%)	Compare
AZTA Azenta, Inc.	$1.6B	— (loss-making)	— (loss-making)	+12.04% (above 0%: growing)	n/m	−134.69% (below 0%: shrinking)	44.89%	(2.59%)	Compare
STAA STAAR Surgical Company	$1.1B	304×	103×	+111.04% (above 0%: growing)	n/m	+166.10% (above 0%: growing)	74.55%	10.80%	Compare
Median of peers	$2.4B	281×	103×	+12.43%	—	−10.27%	56.11%	3.81%

All 55 Medical Instruments & Supplies stocks →

LeMaitre Vascular, Inc. (LMAT) key facts

Strength: LeMaitre Vascular, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $249.6 million, up 13.5% from fiscal 2024.
Strength: Net income was $57.7 million, or $2.55 per share (basic), a net margin of 23.1%.
LeMaitre Vascular, Inc. (LMAT) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LMAT traded at $80.82, a market capitalization of $1.9 billion.
At that price the stock trades at 27.9× trailing-twelve-month earnings and 7.0× sales; its P/E is higher than 9% of its own readings over the past ten years.
LeMaitre Vascular, Inc. pays an annual dividend of $0.95 per share, a yield of 1.18%, with a payout ratio of 33.3%.
Return on equity was 15.8% and debt-to-equity 0.40.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 6.99 (safe zone) for fiscal 2025.